Article February 16, 2009

The Safety of Olanzapine in Adolescents With Schizophrenia or Bipolar I Disorder: A Pooled Analysis of 4 Clinical Trials

Ludmila A. Kryzhanovskaya, M.D., Ph.D.; Carol K. Robertson-Plouch, D.V.M.; Wen Xu, Ph.D.; Janice L. Carlson, Ph.D.; Karen M. Merida, B.S.; Ralf W. Dittmann, M.D., Ph.D.

J Clin Psychiatry 2009;70(2):247-258

Article Abstract
‘ ‹’ ‹

Objective: To describe the safety of olanzapine treatment in adolescents (aged 13­17 years) with schizophrenia or bipolar I disorder, and to compare these data with those of olanzapine-treated adults.

Data Sources and Study Selection: Placebo-controlled database, adolescents: acute phase of 2 double-blind, placebo-controlled trials (3­6 weeks; olanzapine, N=179, mean age=15.5 years; placebo, N=89, mean age=15.7 years); overall adolescent olanzapine exposure database, adolescents: 4 trials (e.g., the 2 aforementioned studies, each with a 26-week open-label extension phase, and 2 open-label, 4.5- and 24-week trials; N=454, mean age=15.9 years); and adult database: 84 clinical trials of up to 32 weeks.

Data Synthesis: The mean daily dosage of olanzapine was 10.6 mg/day (exposure=48,946 patient days). In the overall adolescent olanzapine exposure database, the most common adverse events included increased weight (31.7%), somnolence (19.8%), and increased appetite (17.4%). In up to 32 weeks of treatment, when compared with adults, adolescents from the overall adolescent olanzapine exposure database gained statistically significantly more weight (7.4 kg vs. 3.2 kg, p<.001); statistically significantly more adolescents gained ≥7% of their baseline weight (65.1% vs. 35.6%, p<.001). Adolescents experienced statistically significant within-group baseline-to-endpoint changes in fasting glucose (p<.001), total cholesterol (p=.002), triglycerides (p=.007), and alanine aminotransferase (p<.001). Two patients from the overall adolescent olanzapine exposure database (0.4%) attempted suicide; 13 (2.9%) had suicidal ideation. In the placebo-controlled database, adolescents had statistically significant baseline-to-endpoint increases in prolactin (11.4 micrograms/L, p<.001); 47.4% had high prolactin levels.

Conclusion: The types of adverse events in olanzapine-treated adolescents appear to be similar to those of adults. The magnitude and incidence of weight and prolactin changes were greater in adolescents.

‘ ‹’ ‹’ ‹’ ‹’ ‹

Continue Reading...

Did you know members enjoy unlimited free PDF downloads as part of their subscription? Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.

Subscribe Now

Already a member? Login

Purchase PDF for $40.00

Members enjoy free PDF downloads on all articles. Join today